Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EPO906 in Metastatic Carcinoid and Neuroendocrine Tumors
NCT00050349Phase 2Completed
- Sponsor
- Novartis
- Start
- Jul 2002
- Primary completion
- Apr 2007
- Modality
- Covalent Small Molecules, RNA-Targeting Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of patupilone in Carcinoid Tumor (CT), Neuroendocrine Neoplasm (NEN), sponsored by Novartis. Started Jul 2002; status: completed.
02
Drugs
patupilone
03
Conditions
Carcinoid Tumor (CT)Neuroendocrine Neoplasm (NEN)
Beyond the preview
Go deeper on NCT00050349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00050349.